| Document |
Document Title |
|
WO/2006/038865A1 |
The present invention relates to novel nucleotides and to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament. More particularly, the present in...
|
|
WO/2006/035796A1 |
A compound having SGLT1 and/or SGLT2 inhibitory activity which is usable as a preventive or therapeutic agent for diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, obesity, etc. It is a 1-(β-D-...
|
|
WO/2006/037024A2 |
The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of administer...
|
|
WO/2006/033709A2 |
Compounds of Formulae I-XVI, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral diseases including hepatitis C viral infection, cancer, diabetes, and oth...
|
|
WO/2006/032087A1 |
The invention relates generally to virus resistant plants, wherein the plants are resistant to aphid transmitted viruses. In particular, the invention relates to a method for protecting a plant from aphid-borne viral infection, comprisin...
|
|
WO/2006/034154A2 |
The present invention relates to salts of 5-azacytidine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the 5-azacytidine salts are also provided, including methods of admi...
|
|
WO/2006/032921A1 |
The present invention relates to a compound of formula (1), or a pharmaceutically acceptable salt thereof, Formula: (1); wherein: R1 is a substituted aryl or heteroaryl group bearing at least one nitro or azido group or is an optionally ...
|
|
WO/2006/030803A1 |
A purinenucleoside derivative modified in the 8-position which is useful for diseases attributable to abnormality in plasma uric acid level. It is a purinenucleoside derivative modified in the 8-position which is represented by the follo...
|
|
WO/2006/030980A1 |
It is intended to provide an agent and a food for preventing/improving functional digestive disorder which contains, as the active ingredient, at least one member selected from among glutamic acid, 5’-nucleotides and salts thereof.
|
|
WO/2006/028618A1 |
The invention provides compounds having the following general formula (I) wherein X, R1, R2, R7 and Z are as described herein.
|
|
WO/2006/029065A1 |
Disclosed are prodrugs of inactivators of 06-alkylguanine-DNA alkyltransferase (AGT). The prodrugs are cleavable by the (3-glucuronidase enzyme, which is either administered to the patient or produced by necrotic tumor cells. The prodrug...
|
|
WO/2006/026651A1 |
Disclosed are syntheses suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, a...
|
|
WO/2006/026656A1 |
The present invention provides pharmaceutical compositions comprising Compound 003 or metabolites thereof in combination with one or more carboxylesterase inhibitors. The invention provides methods for inhibiting cellular proliferation a...
|
|
WO/2006/025154A1 |
The invention aims at providing oligonucleotides modified at the 3' end which are excellent in penetration through cell membrane, resistance to nuclease, and the ability to form double strands and whose production was difficult in the pr...
|
|
WO/2006/022323A1 |
Disclosed is a novel phosphoramidite compound which is useful for synthesis of an oligo-RNA. Specifically disclosed is a phosphoramidite compound represented by the following general formula (1). [In the formula, Bx represents a nucleic ...
|
|
WO2005026184A9 |
The invention provides compositions the comprise nucleotides and/or nucleosides having blocking groups at 2'-positions of sugar moieties. Methods of synthesizing these nucleic acids are also provided.
|
|
WO/2006/023272A1 |
The invention provides compounds having the following general formula (I) wherein X, R1, R2, R7 and Z are as described herein.
|
|
WO/2006/021341A1 |
4-Amino-1-((2R,3S,4S,5R)-5-azido-3,4-diyhdroxy-5-hydroxymeth
yl-tetrahydrofuran-2-yl)-1H-pyrimidin-2-one (I:R1=R2=R3=R4=H) and prodrugs thereof are hepatitis C (HCV) polymerase inhibitors. Also disclosed are compositions and methods for ...
|
|
WO/2006/020712A1 |
A method of generating synthetic metabolites of tanaproget derivatives thereof is provided. These compounds and methods of using these derivatives for detecting tanaproget metabolites in samples are provided.
|
|
WO/2006/017052A1 |
Disclosed is a synthesis suitable for large scale manufacture of novel compounds that are partial and full A1 adenosine receptor agonists having the structure of formula (I), wherein R is optionally substituted phenyl, that are useful fo...
|
|
WO/2006/014387A1 |
Orthogonally protected 3'-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3'-amino group in the presence of the unprotected nucleoside base.
|
|
WO2005111056B1 |
Novel esters of adenosine nucleosides and carboxylic acid, of formula 1, wherein R
|
|
WO/2006/005064A2 |
Compositions and methods for detecting 5-methylcytosine in a nucleic acid are disclosed. A 5-methylcytosine discriminator, which is a deoxyribonucleosidetriphosphate comprising a cytosine-pairing moiety such as a guanosine and a moiety w...
|
|
WO/2006/000883A2 |
This invention relates to an improved process for the industrial manufacture of S-adenosyl-L-methionine (SAMe) of Formula (I), which consists of stereo-selective methylation of S-adenosyl-L-homocysteine (SAH) Formula (II) with the enrich...
|
|
WO/2005/123755A2 |
This invention provides novel 8-carbyl substituted Camps (adenosine 3′, 5′-cyclic monophosphorothioate) and a novel procedures for the preparation of 8-Br-cAMP, a key starting material.
|
|
WO/2005/121361A2 |
The present invention relates to a method for detecting sequence specific methylation in a biomolecule, comprising: (a) contacting a biomolecule with an S-adenosyl-L-methionine-dependent methyltransferase in the presence of a detectable ...
|
|
WO/2005/121162A1 |
The invention is directed to 3-ß-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or pr...
|
|
WO/2005/117910A2 |
The invention relates to Purine Derivatives, compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal’s rate of metabolism, protecting an animal’s heart against myocardial damage during c...
|
|
WO/2005/118608A2 |
This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclsoed nucleotides are also provided.
|
|
WO/2005/116043A1 |
The invention relates to a compound having formula (I), wherein: X = O, S or -CH2-; B = a purine or pyrimidine base; L1, L2, = an oxycarbonyl, thiocarbamate, carbonate and carbamate group, an oxygen atom, or together form a ketal or thio...
|
|
WO/2005/116044A1 |
An industrially preferable process for producing the indolopyrrolocarbazole derivative (I) or a pharmaceutically acceptable salt thereof, which are useful as an anticancer agent. A compound represented by the general formula (V): a solva...
|
|
WO/2005/113569A1 |
The present invention relates to novel 3-triazolyl-galactosides, the use of said triazolyl-galactosides as medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galactin to recept...
|
|
WO/2005/108411A2 |
The present invention is directed to amidites useful in the synthesis of oligonucleotides comprising at least one RN moiety, and to methods of using such amidites in the synthesis of such oligonucleotides. The inventive amidites possess ...
|
|
WO/2005/097816A1 |
A compound of the formula (I) wherein the bond between carbon atoms 22 and 23 indicated with a broken line is a single or double bond, m is 0 or 1, R1 represents a C1-C12alkyl, C3-C8cycloalkyl or C2-C12alkenyl group, R2 represents a hydr...
|
|
WO/2005/096706A2 |
The present invention provides a new immunogen, a novel antibody having high specificity for MTA (5'-deoxy-5'-methylthioadenosine), methods of treatment and medicaments prepared using said antibody, and sensitive assays for measuring spe...
|
|
WO/2005/097814A2 |
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject...
|
|
WO/2005/094322A2 |
The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat tumors and cancer by one or a combination of (i) administering triciribine only to patients which according to a diagno...
|
|
WO/2005/095430A1 |
A process for the preparation of Gemcitabine hydrochloride of formula (I) of extra high purity by the reaction of (R) -2,3-0-isopropylidene glyceraldehyde of formula (II) with ethyl bromo difluoroacetate of formula (III) followed by hydr...
|
|
WO/2005/092909A1 |
A process for producing a ribonucleotide analogue having high stereoregularity. The process, which is for producing a ribonucleotide analogue having high stereoregularity represented by the formula (IV) or (V), is characterized by conden...
|
|
WO/2005/092910A1 |
The invention relates to a temperature-stable labelling reagent having formula (0), wherein: R1 represents H or an alkyl, aryl or substituted aryl group; R2 represents a detectable label or at least two detectable labels which are inter-...
|
|
WO/2005/090349A1 |
A compound which has excellent anti-HIV activity, is effective also against polypharmacy-resistant HIV strains having resistance to two or more anti-HIV drugs, especially AZT, DDI, DDC, D4T, 3TC, etc., is lowly cytotoxic, and has resista...
|
|
WO/2005/090370A1 |
Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections, cell proliferation and bone metabolism. The compounds provided herein are alkyl esters...
|
|
WO/2005/087788A2 |
A process is provided for the preparation of lipophilic monoesters of formula (3) and their stereoisomers. The process includes the steps of esterification of a phosphonate with a lipophilic alcohol, then allowing the resultant product t...
|
|
WO/2005/085272A1 |
A boranophosphate oligomer which is useful as an antisense molecule, etc. and can withstand practical use; and a boranophosphate monomer represented by the following formula (1). The oligomer is obtained by condensing the monomer in the ...
|
|
WO/2005/084653A2 |
Use of compounds of general formula (A) as medicaments is described, in particular for the treatment of pain or inflammation; wherein: (I) when X = OH, R2 = NH2, R5 = CH2OH, R6 = H , R1 is C5-C6 alkoxy, OCH2Cyclopropyl, O-(2,2,3,3-tetraf...
|
|
WO/2005/084367A2 |
This invention provides a method for determining the sequence of a DNA or an RNA, wherein (i) about 1000 or fewer copies of the DNA or RNA are bound to a solid substrate via 1,3-dipolar azide-alkyne cycloaddition chemistry and (ii) each ...
|
|
WO/2005/084192A2 |
Compounds of Formula (I), stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of hepatitis C viral infection are described.
|
|
WO/2005/085268A2 |
The present invention relates to novel phosponate nucleosides, more specifically to novel phosponalkoxy substituted nucleosides. The invention further relates to compounds having HIV (Human Immunodeficiency Virus) replication inhibiting ...
|
|
WO/2005/085271A1 |
The invention aims at developing a system for constructing cyanoethyl ethers efficiently under mild conditions and probability of the ethers as functional groups for imparting specific functions and thus making a contribution to the crea...
|
|
WO/2005/085270A1 |
An artificial nucleic acid which employs a precise copy of the hydrogen bond mode of a protonated cytosine base and has a high triplex-forming ability. It is a nucleic acid derivative represented by the following general formula (I) or a...
|
